Siponimod (hemifumarate)

Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively) . Siponimod hemifumarate can be used for multiple sclerosis (MS) research[1][2].

Product Specifications

CAS Number

[1234627-85-0]

Product Name Alternative

BAF-312 (hemifumarate)

UNSPSC

12352005

Hazard Statement

H361, H373, H411

Target

LPL Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/siponimod-hemifumarate.html

Purity

99.64

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

O=C(C1CN(CC2=CC=C(/C(C)=N/OCC3=CC=C(C4CCCCC4)C(C(F)(F)F)=C3)C=C2CC)C1)O.OC(/C=C/C(O)=O)=O.[1/2]

Molecular Formula

C29H35F3N2O3.1/2C4H4O4

Molecular Weight

574.63

Precautions

H361, H373, H411

References & Citations

[1]Pan S, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4 (3) :333-7.|[2]McGinley M, et al. Prospects of siponimod in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2018 Jul 17;11:1756286418788013.|[3]Behrangi N, et al. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells. 2019 Jan 7;8 (1) :24.